Physician profile
Elizabeth Anne Thiele
NPI 1982670535
$277,849.31
in general payments reported to CMS, 2019-2025
26 companies · $36K in 2025
The $36K reported for 2025 was more than what 97% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80K · 2020: $40K · 2021: $30K · 2022: $49K · 2023: $19K · 2024: $23K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $47K · Honoraria: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,834 · Travel and Lodging: $8,128 · Food and Beverage: $2,635 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $47,419.26 |
| Honoraria | $11,014.60 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,834.00 |
| Travel and Lodging | $8,128.18 |
| Food and Beverage | $2,634.59 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Greenwich Biosciences, INC. | $84,006.73 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $55,203.85 | 2022-2025 | Epidiolex |
| Ucb, INC. | $32,105.88 | 2019-2025 | Fintepla |
| Gw Pharma Limited | $27,371.36 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19,499.27 | 2022 | |
| Gw Research Limited | $9,871.00 | 2019 | |
| Livanova USA, INC. | $6,594.78 | 2021-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Radius Health, INC. | $6,365.12 | 2021-2022 | |
| Zogenix INC. | $6,312.00 | 2020-2021 | |
| Biocodex, INC. | $6,248.16 | 2023-2025 | Diacomit |
| Ucb Sa | $4,803.01 | 2025 | Fintepla |
| Lundbeck LLC | $3,919.10 | 2025 | |
| Btg International INC. | $2,941.08 | 2022 | |
| Eisai Co., Ltd. | $2,400.00 | 2021 | |
| Aquestive Therapeutics, INC. | $2,040.00 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immedica Pharma US, INC. | $1,908.84 | 2022 | |
| West Therapeutics Development, LLC | $1,750.00 | 2019 | |
| Eisai INC. | $1,680.00 | 2020 | |
| Nobelpharma America, LLC | $1,290.00 | 2024 | |
| Azurity Pharmaceuticals, INC. | $1,200.00 | 2021 | |
| Sk Life Science, INC. | $226.09 | 2021-2023 | Xcopri |
| Cadwell Industries, INC | $65.81 | 2025 | |
| Merck Sharp & Dohme LLC | $25.70 | 2025 | Welireg |
| Sunovion Pharmaceuticals INC. | $21.53 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Thiele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.